Passa al contenuto
Merck
Tutte le immagini(1)

Documenti

A0040000

Acebutolol hydrochloride

European Pharmacopoeia (EP) Reference Standard

Sinonimo/i:

N-(3-Acetyl-4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl)butanamide

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C18H28N2O4 · HCl
Numero CAS:
34381-68-5
Peso molecolare:
372.89
Numero MDL:
MFCD00078860
Codice UNSPSC:
41116107
ID PubChem:
329770566
NACRES:
NA.24

Grado

pharmaceutical primary standard

Famiglia di API

acebutolol

Produttore/marchio commerciale

EDQM

applicazioni

pharmaceutical (small molecule)

Formato

neat

Temperatura di conservazione

2-8°C

Stringa SMILE

Cl.CCCC(=O)Nc1ccc(OCC(O)CNC(C)C)c(c1)C(C)=O

InChI

1S/C18H28N2O4.ClH/c1-5-6-18(23)20-14-7-8-17(16(9-14)13(4)21)24-11-15(22)10-19-12(2)3;/h7-9,12,15,19,22H,5-6,10-11H2,1-4H3,(H,20,23);1H
KTUFKADDDORSSI-UHFFFAOYSA-N

Informazioni sul gene

human ... ADRB1(153)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Categorie correlate

Descrizione generale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.

Applicazioni

Acebutolol hydrochloride EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Confezionamento

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Altre note

Sales restrictions may apply.

Prodotti correlati

N° Catalogo
Descrizione
Determinazione del prezzo

1000601

Acebutolol hydrochloride, United States Pharmacopeia (USP) Reference Standard

1000612

Acebutolol Related Compound A, United States Pharmacopeia (USP) Reference Standard

Y0000127

Acebutolol impurity C, European Pharmacopoeia (EP) Reference Standard

Y0000128

Acebutolol impurity I, European Pharmacopoeia (EP) Reference Standard

Y0000359

Acebutolol impurity B, European Pharmacopoeia (EP) Reference Standard

1000699

Acebutolol Related Compound I, United States Pharmacopeia (USP) Reference Standard

1000623

Acebutolol Related Compound B, United States Pharmacopeia (USP) Reference Standard

PHR2824

Acebutolol Related Compound A

Pittogrammi

Exclamation mark
GHS07

Avvertenze

Warning

Indicazioni di pericolo

H312 + H332

Classi di pericolo

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Choose from one of the most recent versions:

Certificati d'analisi (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Silvio Abati et al.
The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 26(4), 369-372 (2012-10-09)
The aim of this study was to explore the relationship between periodontal health and pregnancy outcomes in a large cohort of Italian postpartum women. 750 postpartum women were enrolled in a case-control study within 5 days from delivery at three
Pratap Neelakantan et al.
Blood, 121(14), 2739-2742 (2013-02-06)
Several groups have shown that that the BCR-ABL1 transcript level measured at 3 or 6 months after starting treatment with tyrosine kinase inhibitors strongly predicts clinical outcomes for patients with chronic myeloid leukemia. In this work, we asked whether the
Darren P Martin et al.
Archives of virology, 156(8), 1463-1469 (2011-04-13)
Recombination has profoundly shaped the evolution of viruses in the family Geminiviridae and has been studied extensively in the two best characterised geminivirus lineages: the dicotyledonous plant infecting begomoviruses and the monocotyledonous plant infecting mastreviruses. Here, we demonstrate that the
Iu M Alekseeva et al.
Kardiologiia, 47(12), 24-34 (2008-02-12)
Beta-blocking agents (BB) decrease mortality particularly sudden in post-myocardial infarction patients and in patients with chronic heart failure that is closely related to heart rate (HR) lowering at rest. The hypothesis exists that BB decrease mortality due to increase of
Suguru Kurokawa et al.
Journal of nutritional science and vitaminology, 57(4), 298-305 (2011-11-02)
Selenocysteine lyase (SCL) catalyzes the decomposition of L-selenocysteine to yield L-alanine and selenium by acting exclusively on l-selenocysteine. The X-ray structural analysis of rat SCL has demonstrated how SCL discriminates L-selenocysteine from L-cysteine on the molecular basis. SCL has been
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.